4559:TYO
Zeria Pharmaceutical Co Ltd
1 898,00 ¥
0,00%
(0,00) 1 d.
2. okt., 15:30:00 GMT+9 · JPY
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: 4559…
Tirgus kapitalizācija
95,13 mljrd.
Vid. apjoms
167,72 tūkst.
Apjoms
0,00
Dividende
2,58%
Ceturkšņa dividendes
12 ¥
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 29. sept.
Cenas/peļņas attiecība
10,17
Augstākā 52 ned.
2 434 ¥
Zemākā 52 ned.
1 878 ¥
Peļņa uz vienu akciju
187 ¥
Apgrozībā esošās akcijas
50,11 milj.
Darbinieku skaits
2 tūkst.
Tirgus kapitalizācija
95,13 mljrd.
Vid. apjoms
167,72 tūkst.
Apjoms
0,00
Dividende
2,58%
Ceturkšņa dividendes
12 ¥
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 29. sept.
Cenas/peļņas attiecība
10,17
Augstākā 52 ned.
2 434 ¥
Zemākā 52 ned.
1 878 ¥
Peļņa uz vienu akciju
187 ¥
Apgrozībā esošās akcijas
50,11 milj.
Darbinieku skaits
2 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Proactive financial news
·
pirms 12 minūtēm
Nova Minerals to host investor webinar on Estelle and US antimony strategy
Simply Wall Street
·
pirms 18 minūtēm
EasySource Marketplace Listing Might Change The Case For Investing In Paylocity (PCTY)
FXLeaders
·
pirms 1 stundas
Dow Jones and Nasdaq Futures Open Higher as Buyers Target New Records
Profils
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
Par “Zeria Pharmaceutical Co Ltd”
ĢenerāldirektorsSachiaki Ibe
Darbinieki1,75 tūkst.
Dibināšanas datums1955. gada 22. dec.
Galvenais birojs-
Sektors-
Tīmekļa vietnezeria.co.jp